Sugi Predict

Sugi Predict / Targets / GSPT1

GSPT1

Eukaryotic peptide chain release factor GTP-binding subunit ERF3A · P15170 · GSPT1 on Sugi Atlas →

22,279 patent compounds predicted against GSPT1, 13,081 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1413383 SCHEMBL1413383 0.69 13/20
SCHEMBL2334587 SCHEMBL2334587 0.53 13/20
SCHEMBL2337722 SCHEMBL2337722 0.54 12/20
SCHEMBL2342025 SCHEMBL2342025 0.54 12/20
SCHEMBL2337176 SCHEMBL2337176 0.52 12/20
SCHEMBL69197 SCHEMBL69197 0.61 11/20
SCHEMBL70500 SCHEMBL70500 0.59 11/20
SCHEMBL70502 SCHEMBL70502 0.59 11/20
SCHEMBL69198 SCHEMBL69198 0.58 11/20
SCHEMBL70103 SCHEMBL70103 0.57 11/20
SCHEMBL70504 SCHEMBL70504 0.57 11/20
SCHEMBL61575 SCHEMBL61575 1.00 10/20
SCHEMBL60782 SCHEMBL60782 0.60 10/20
SCHEMBL69518 SCHEMBL69518 0.58 10/20
SCHEMBL68157 SCHEMBL68157 0.85 9/20
SCHEMBL1413473 SCHEMBL1413473 0.85 9/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL62087) 0.84 9/20
SCHEMBL68661 SCHEMBL68661 0.78 9/20
SCHEMBL1413381 SCHEMBL1413381 0.77 9/20
SCHEMBL1413600 SCHEMBL1413600 0.67 9/20

Clinical trials — most relevant to GSPT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
A Pharmacodynamic Study of Leuprorelin Gelatin-Free Formulation in Female Subjects With Uterine Fibroids. PHASE2COMPLETED
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Pharmacogenetics of Response to GLP1R Agonists PHASE1RECRUITING
Follicle-Stimulating Hormone (FSH) and the Onset of Puberty EARLY_PHASE1COMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D) EARLY_PHASE1COMPLETED
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing nanCOMPLETED
Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein nanCOMPLETED
Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia) nanUNKNOWN
Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine nanCOMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Investigation of Asprosin a Novel Adipokine in Periodontitis nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome nanACTIVE_NOT_RECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Inherited Reproductive Disorders nanRECRUITING
Genetic Variants Associated With Adolescent Suicide Attempts nanCOMPLETED
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus nanNOT_YET_RECRUITING
A Post Marketing Assessment of Gonal f Solution for Injection in a Prefilled Pen for Follicular Stimulation in in Vitro Fertilisation/Embryo Transfer (IVF-ET) Cycles nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Effect of Liraglutide on Clock Genes nanUNKNOWN
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GSPT1 binder may also engage these)

ProteinNameSimilarity
Q32PH8 — 0.988 Q32PH8 →
P62631 — 0.988 P62631 →
Q5R4B3 — 0.988 Q5R4B3 →
Q8R050 — 0.985 Q8R050 →
EEF1A2 Elongation factor 1-alpha 2 0.985 landscape →
P50256 — 0.985 P50256 →
Q2KHZ2 — 0.985 Q2KHZ2 →
P02993 — 0.985 P02993 →
P27592 — 0.985 P27592 →
P25166 — 0.984 P25166 →
Q2HJN6 — 0.984 Q2HJN6 →
Q6AXM7 — 0.984 Q6AXM7 →
P62632 — 0.984 P62632 →
Q8LPC4 — 0.984 Q8LPC4 →
P86934 — 0.984 P86934 →
P90519 — 0.984 P90519 →
Q69ZS7 — 0.983 Q69ZS7 →
A5DPE3 — 0.983 A5DPE3 →
A2Q0Z0 — 0.983 A2Q0Z0 →
P51554 — 0.983 P51554 →
P25698 — 0.983 P25698 →
P68105 — 0.983 P68105 →
Q59QD6 — 0.983 Q59QD6 →
Q27140 — 0.983 Q27140 →
P86939 — 0.983 P86939 →
Q41011 — 0.983 Q41011 →
Q41803 — 0.983 Q41803 →
Q9Y700 — 0.983 Q9Y700 →
TUFM Elongation factor Tu, mitochondrial 0.983 landscape →
Q2HJN8 — 0.983 Q2HJN8 →